^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MUC17 (Mucin 17)

    i
    Other names: MUC17, Mucin 17, Cell Surface Associated, Small Intestinal Mucin-3, Mucin-17, MUC-17, MUC-3, MUC3, Small Intestinal Mucin MUC3, Membrane Mucin MUC17, Secreted Mucin MUC17
    Associations

    News

    Trials
    23d
    Bile duct tumor thrombus (intraductal polypoid growth)-positive intrahepatic cholangiocarcinoma: clinicopathologic and genomic analysis. (PubMed, J Pathol)
    These results highlight the importance of evaluating BDTT in SDT, as it may be the main route of hilar extension in aggressive cases.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • NF1 (Neurofibromin 1) • BAP1 (BRCA1 Associated Protein 1) • KMT2D (Lysine Methyltransferase 2D) • MUC1 (Mucin 1) • SMAD4 (SMAD family member 4) • MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • MUC4 (Mucin 4, Cell Surface Associated) • CDX2 (Caudal Type Homeobox 2) • MUC2 (Mucin 2) • RSPO3 (R-Spondin 3) • CACNA1A (Calcium Voltage-Gated Channel Subunit Alpha1 A) • MUC17 (Mucin 17) • MUC5AC (Mucin 5AC) • MUC6 (Mucin 6) • PTPRK (Protein Tyrosine Phosphatase Receptor Type K) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    |
    FGFR2 mutation • FGFR2 fusion • FGFR2 rearrangement
    1m
    Molecular characteristics and prognosis of triple negative breast cancer stratified by HER2 status. (PubMed, Chin Med J (Engl))
    Taken together, our study reflected the impact of the HER2 status on the clinicopathological and molecular features of TNBCs, which might offer additional introspection and improvement for translational studies and therapeutic decisions for TNBCs.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • FAT3 (FAT Atypical Cadherin 3) • CSMD3 (CUB And Sushi Multiple Domains 3) • MUC17 (Mucin 17)
    |
    PIK3CA mutation • HER-2 mutation • HER-2 expression • PTEN mutation
    3ms
    CAR-T cell therapy targeting MUC17 in gastric tumors. (PubMed, J Immunother Cancer)
    These findings support MUC17 as a promising immunotherapeutic target for gastric cancer and demonstrate how targeting glycocalyx-associated antigens can expand the range of surface proteins amenable to CAR-T cell-based therapies in solid tumors.
    Journal • IO biomarker
    |
    MUC17 (Mucin 17)
    4ms
    Spatial transcriptomic analysis of foveolar-type gastric adenoma with raspberry-like appearance. (PubMed, Virchows Arch)
    FGA-RA exhibits a distinctive mucin profile reflecting incomplete intestinal differentiation due to KLF4 dysfunction. The characteristic raspberry-like morphology may be a consequence of VEGF-driven angiogenesis induced by chronic stimulation of a superficially compromised epithelium, suggesting that this unique appearance arises from sequential epithelial and stromal alterations orchestrated by KLF4 mutation.
    Journal
    |
    FLT1 (Fms-related tyrosine kinase 1) • KLF4 (Kruppel-like factor 4) • MUC2 (Mucin 2) • MUC17 (Mucin 17) • MUC5AC (Mucin 5AC)
    4ms
    Unravelling key genes and molecular pathways in gastric inflammation-to-cancer transition through causal discovery: implications for early diagnosis and therapy. (PubMed, SAGE Open Med)
    Nine key genes-mucin 17, brain-expressed X-linked 2, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3, Ras association domain family member 2, NLR family pyrin domain-containing 7, interferon regulatory factor 4, carbamoyl phosphate synthetase 1, nucleoporin 210 and neuronal differentiation 2-were identified, all of which were significantly associated with gastric cancer survival. This study integrates graph neural networks and causal inference to identify critical genes involved in gastric inflammation-cancer progression, providing novel insights into the pathogenesis of gastric cancer and potential biomarkers for validation in future studies.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • IRF4 (Interferon regulatory factor 4) • BEX2 (Brain Expressed X-Linked 2) • MUC17 (Mucin 17)
    5ms
    Somatic variants and frequencies of familial myeloma germline predisposition genes among patients within the CoMMpass dataset. (PubMed, Expert Rev Hematol)
    Moreover, variant types, consequences, and associated demographics revealed similar rates in young myeloma patients (≤50 years) and patients with a first-degree family history of hematological malignancy. This study highlights a significant rate of pathogenic somatic variants in germline predisposition genes of familial myeloma, suggesting candidate genes to be investigated in myelomagenesis.
    Journal
    |
    ARID1A (AT-rich interaction domain 1A) • LRP1B (LDL Receptor Related Protein 1B) • EP300 (E1A binding protein p300) • DCHS1 (Dachsous Cadherin-Related 1) • MUC17 (Mucin 17)
    5ms
    Prognostic model of ubiquitination-related genes in ovarian cancer based on transcriptomic analysis and experimental validation. (PubMed, Front Immunol)
    FBXO45 is a key E3 ubiquitin ligase in ovarian cancer, promoting growth, spread and migration via the Wnt/β-catenin pathway. Ubiquitination-related markers provide reliable prognostic insights and reflect the immune microenvironment in ovarian cancer, offering a basis for clinical targeting strategies.
    Journal
    |
    CD8 (cluster of differentiation 8) • MUC17 (Mucin 17) • LRRK2 (Leucine Rich Repeat Kinase 2) • RYR2 (Ryanodine Receptor 2)
    5ms
    Whole-exome sequencing reveals the mutational landscape of head and neck lymphoepithelioma-like carcinoma. (PubMed, Oral Oncol)
    In addition, interrogation of the Drug-Gene Interaction Database highlighted putative therapeutic targets such as CDK13, MUC16, and MUC17. While preliminary, these findings establish the first comprehensive mutational blueprint of HNLEC, providing novel insights into its pathogenesis, potential prognostic determinants, and therapeutic vulnerabilities, and laying a foundation for future translational and clinical research.
    Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated) • MUC5B (Mucin 5B, Oligomeric Mucus/Gel-Forming) • XIRP2 (Xin Actin Binding Repeat Containing 2) • CDK13 (Cyclin Dependent Kinase 13) • EPPK1 (Epiplakin 1) • MUC17 (Mucin 17)
    6ms
    Identification of neoantigen epitopes in cervical cancer by multi-omics analysis. (PubMed, Eur J Med Res)
    Our analysis highlights the potential of PCLO as a candidate gene for enhancing immune cell infiltration and activating immune responses in tumors. The peptides SISRFTLEK (PCLOL4169F) and LSEAGHFFY (PCLOA3000S) are promising targets for tumor vaccines.
    Journal
    |
    CD8 (cluster of differentiation 8) • CREBBP (CREB binding protein) • HUWE1 (HECT UBA And WWE Domain Containing E3 Ubiquitin Protein Ligase 1) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • MUC17 (Mucin 17) • PCLO (Piccolo Presynaptic Cytomatrix Protein)
    7ms
    Camrelizumab, an Anti-PD-1 Monoclonal Antibody, Plus Carboplatin and Nab-Paclitaxel as First-Line Setting for Extensive-Stage Small-Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis. (PubMed, MedComm (2020))
    Collectively, this trial suggested that camrelizumab plus carboplatin and nab-paclitaxel might be an alternative first-line setting for ES-SCLC. Integration of multiomic data could highlight the complex mechanisms underlying chemo-immunotherapy responses.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MUC17 (Mucin 17) • NEUROG1 (Neurogenin 1)
    |
    carboplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel
    11ms
    Construction of Bispecific T-Cell Engager Radiotracer and Its Micro-PET Evaluation in Pancreatic Cancer. (PubMed, Mol Pharm)
    In summary, the 89Zr-M17C3 radiotracer exhibited high affinity for MUC17 and CD3 and successfully differentiated MUC17-positive tumors from MUC17-negative tumors while simultaneously providing insight into the T-cell distribution. This study highlights the potential of 89Zr-M17C3 as a versatile imaging tool to support patient stratification and therapeutic monitoring in tumor-targeted immunotherapy, particularly for bispecific T-cell engager-based approaches such as AMG199.
    Journal • IO biomarker
    |
    MUC17 (Mucin 17)
    |
    vepsitamab (AMG 199)
    1year
    Whole exome-seq and RNA-seq data reveal unique neoantigen profiles in Kenyan breast cancer patients. (PubMed, Front Oncol)
    The unique neoantigen profiles in our patient group highlight the potential of immunotherapy in personalized breast cancer treatment as well as potential biomarkers for prognosis. The unique mutations producing these neoantigens, compared to other populations, provide an opportunity for validation in a much larger sample cohort.
    Journal • BRCA Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • BRCA2 (Breast cancer 2, early onset) • RB1 (RB Transcriptional Corepressor 1) • HLA-A (Major Histocompatibility Complex, Class I, A) • MUC16 (Mucin 16, Cell Surface Associated) • HLA-B (Major Histocompatibility Complex, Class I, B) • CDH23 (Cadherin Related 23) • HLA-C (Major Histocompatibility Complex, Class I, C) • MUC17 (Mucin 17)
    |
    HLA-A*02 • HLA-A*30